Physician profile
Patrick Thompson
NPI 1417938630
$7,372.39
in general payments reported to CMS, 2019-2025
26 companies · $1,180 in 2025
The $1,180 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,024 · 2020: $379 · 2021: $1,016 · 2022: $968 · 2023: $694 · 2024: $1,111 · 2025: $1,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,984.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,836.18 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $1,066.92 | 2019-2024 | Xarelto |
| Amgen INC. | $789.53 | 2019-2025 | Repatha, Krystexxa, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $721.66 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $242.71 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $224.66 | 2019-2020 | |
| Lilly USA, LLC | $206.63 | 2019-2020 | |
| Pfizer INC. | $165.55 | 2019-2025 | |
| Bard Peripheral Vascular, INC. | $153.58 | 2021 | |
| Celgene Corporation | $130.47 | 2019 | |
| Abbott Laboratories | $129.82 | 2023 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $109.37 | 2022 | |
| Glaxosmithkline, LLC. | $99.72 | 2019-2020 | |
| Genzyme Corporation | $92.01 | 2019-2020 | |
| Esperion Therapeutics, INC. | $83.14 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $67.44 | 2019 | |
| Vivus LLC | $41.97 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.61 | 2019 | |
| Boston Scientific Corporation | $33.45 | 2019 | |
| Edwards Lifesciences Corporation | $29.92 | 2020 | |
| Janssen Biotech, INC. | $25.66 | 2020 | |
| Novo Nordisk INC | $21.55 | 2020 | |
| Horizon Therapeutics Plc | $19.61 | 2019 | |
| Gilead Sciences, INC. | $15.57 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.81 | 2020 | |
| Antares Pharma, INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.